CENTRAL TRUST Co Trims Stake in Humana Inc. (NYSE:HUM)

CENTRAL TRUST Co lessened its position in Humana Inc. (NYSE:HUM) by 14.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 230 shares of the insurance provider’s stock after selling 39 shares during the quarter. CENTRAL TRUST Co’s holdings in Humana were worth $73,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in HUM. CarsonAllaria Wealth Management Ltd. lifted its position in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares during the period. Atwood & Palmer Inc. bought a new position in shares of Humana in the 3rd quarter worth about $29,000. Hantz Financial Services Inc. purchased a new position in Humana during the 2nd quarter valued at about $35,000. Family Firm Inc. bought a new stake in Humana during the second quarter worth about $37,000. Finally, Hollencrest Capital Management purchased a new stake in Humana in the second quarter worth about $40,000. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

NYSE HUM opened at $260.73 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $527.18. The stock has a market cap of $31.39 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 2.04 and a beta of 0.50. The company’s 50 day moving average is $306.51 and its two-hundred day moving average is $336.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the firm earned $8.94 EPS. The company’s revenue was up 10.4% on a year-over-year basis. As a group, research analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.36%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is currently 25.25%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HUM shares. Oppenheimer dropped their price target on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $519.00 to $253.00 in a report on Monday, October 7th. Truist Financial reduced their price target on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a report on Friday, October 11th. Stephens reiterated an “equal weight” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.